Abstract
Ursu et al.1 outline an absence of neurocognitive deficits and a reduction of anxiety measurements in a prospective single-center study of patients with lymphoma receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapy. Despite the well-studied acute neurotoxicities of CAR T-cell therapy, delayed onset of cognitive dysfunction was not characterized in pivotal clinical trials. With roughly 60% CAR T-cell therapy patients experiencing acute neurologic symptoms to some degree, the postulated absence of long-term sequelae would be surprisingly encouraging.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
